JUVISÉ-PHARMACEUTICALS
4.2.2020 10:32:09 CET | Business Wire | Press release
The French specialty pharmaceutical company, Juvisé Pharmaceuticals is pleased to announce its successful syndication of its EUR 213 million debt package supporting the acquisition of Arimidex® and Casodex® from AstraZeneca, with the collaboration of Société Générale and HSBC, acting as Physical Bookrunners and Mandated Lead Arrangers, BNP Paribas, acting as Mandated Lead Arranger and Lazard acting as financial advisor to Juvisé Pharmaceuticals.
On the back of a strong support from both relationship lenders and institutional investors, syndication was wrapped following a successful and oversubscribed early-bird phase. The covenanted financing is comprised of a EUR 128 million TLB alongside a EUR 85 million TLA. This syndication was made possible through the collaboration with Juvisé Pharmaceuticals financial partners, with whom the company relies on long-term partnership characterized by openness and trust.
This successful syndication is another important step in Juvisé Pharmaceuticals development. It reasserts the company ability to leverage all debt capital instruments to fulfil its growth ambition, while keeping the flexibility and independence in decision making allowed by its privately held structure.
Frédéric Mascha, Founder and President of Juvisé Pharmaceuticals, declared, “We are very pleased that our acquisition debt package was successfully syndicated in this oversubscribed early-bird phase and we would like to thank our financial partners for the trust they have shown in our project. We are proud to see that our commitment towards physicians, patients, and our Pharma partners convinced renowned financial institutions to support our ambitious development plan.”
About Arimidex®
and Casodex®
Arimidex®
(anastrozole
) and Casodex®
(bicalutamide
) are hormone treatments for breast and prostate cancer. The two products are recognized as pillar in those cancer treatments and essential for both patients and physicians.
On 19th December 2019, Juvisé Pharmaceuticals acquired the rights of Arimidex® and Casodex® in 45 countries in Europe and a number of Middle Eastern and African markets.
About Juvisé Pharmaceuticals
Founded in 2008, Juvisé Pharmaceuticals is specialised in manufacturing, distributing and marketing its own branded pharmaceutical products. Juvisé focuses in offering treatments in: (i) Cardiology, (ii) Neuro-Psychiatry and (iii) Oncology.
The company business model consists in acquiring branded assets from large pharmaceutical companies like Novartis, AstraZeneca or Sigma Tau and optimising value creation through maximization of product life cycle.
11 years after its creation, Juvisé Pharmaceuticals has become a recognized international company commercializing its own treatments in 75 countries around the world.
For more information, please visit juvisepharmaceuticals.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005424/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ABB Robotics Partners with NVIDIA to Deliver Industrial-Grade Physical AI at Scale9.3.2026 13:00:00 CET | Press release
ABB Robotics integrates NVIDIA Omniverse libraries into RobotStudio® to deliver physical AI for industry, closing the gap from virtual training to real-world deployment with up to 99% accuracy New RobotStudio HyperReality, available second half of 2026, will fundamentally change how quickly and reliably manufacturers can scale production, reducing costs by up to 40% and accelerating time-to-market by 50% Full range and breadth of industrial applications, with real-world pilot being conducted by Foxconn in consumer electronics assembly At NVIDIA GTC, the robotic workforce company WORKR will showcase how it’s using the solution to help manufacturers across the U.S. addressing critical labor shortages ABB Robotics announced today it is integrating NVIDIA Omniverse libraries into ABB Robotics’ RobotStudio® to help manufacturers deploy physical AI in real world robotics applications. “Today, using NVIDIA accelerated computing and simulation technologies, we have removed the last barriers to
Allegro DVT Launches DWP300 DeWarp Semiconductor IP9.3.2026 13:00:00 CET | Press release
Allegro DVT, the worldwide leader in Semiconductor Video IPs and Video Compliance Tools announces, the addition of its new DWP300 DeWarp IP to its Zinia Pixel Processing IPs portfolio. This latest innovation further reinforces Allegro DVT’s commitment to delivering comprehensive, high-performance solutions for next-generation imaging and video applications. The new DWP300 DeWarp IP is designed for optimal silicon area and power efficiency while offering flexible geometric transformation in real time. It combines a customizable software driver that generates mesh configurations for a wide range of geometric transformations and a dedicated hardware core capable of executing the geometric transformation in real-time on full video. This hybrid Hardware/Software approach enables precise distortion correction while allowing customers to easily adapt the solution to their specific application requirements. With the rapid growth of applications such as automotive surround view, smart surveilla
Kinaxis Announces Amendment to Maximize Size of Normal Course Issuer Bid9.3.2026 12:00:00 CET | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) today announces that, further to its previously announced intention to maximize the size of its normal course issuer bid (the “NCIB”), it has received approval from the Toronto Stock Exchange (the “TSX”) to amend (the “Amendment”) the NCIB, effective on March 11, 2026 (the “Effective Date”), to increase the maximum number of common shares (the “Shares”) that may be repurchased from 1,403,042, representing 5% of the Company’s issued and outstanding Shares as at October 31, 2025, to 2,799,843, representing 10% of the Company’s “public float” as at October 31, 2025, the maximum amount allowable under the rules of the TSX. No other terms of the NCIB have been amended. The Company has already invested US$54 million under its current NCIB. At the average price paid to date for the Shares under the current NCIB, repurchasing 10% of the Shares would represent an additional investment of approximately US$284 million. In its February 4, 2026
Ki Reply and Data Reply Lay the Strategic Foundation for AI Innovation at Siemens Healthineers with “Cerebra”9.3.2026 10:53:00 CET | Press release
Ki Reply and Data Reply, the Reply Group companies specialised respectively in AI-powered software development and data-driven solutions, have partnered with the “CRM Excellence” department of medical technology company Siemens Healthineers to develop “Cerebra“, an advanced AI platform designed to deliver rapid, relevant insights across marketing and sales. The concept proved so successful that “Cerebra” was evolved into an Agent Factory, which now standardises, simplifies, and accelerates the deployment of AI agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260309083025/en/ To support labour-intensive manual research in marketing, and sales, Siemens Healthineers now leverages “Cerebra“, an AI-powered knowledge platform that uses specialised AI agents to consolidate internal and external data. In the fast-moving and highly regulated medical technology market, the ability to analyse information accurately and quickly is
AMINA Becomes First Regulated Bank on 21X, Europe’s First Fully Regulated DLT Trading and Settlement Venue9.3.2026 08:30:00 CET | Press release
Along with Tokeny, the combined tokenisation suite creates a complete tokenisation infrastructure, from regulated custody to onchain trading and settlement AMINA Bank AG (“AMINA”), a Swiss Financial Market Supervisory Authority (FINMA)-regulated crypto bank with global reach, today announces it has become a listing sponsor on 21X, the first fully regulated distributed ledger technology trading and settlement system (DLT TSS) in the European Union. AMINA is the first regulated bank to join the 21X ecosystem as a listing sponsor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260309758719/en/ AMINA, 21X and Tokeny partner for end-to-end solution Combined with AMINA’s existing collaboration with Tokeny for onchain asset issuance, the partnership creates a complete tokenisation infrastructure that addresses a major constraint of institutional adoption: the absence of an end-to-end pathway connecting regulated traditional asset c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom